The impact of PET and SPECT on dosimetry for targeted radionuclide therapy

Zeitschrift fur Medizinische Physik

Volumn 16, Issue 1, 2006, Pages 47-59

  Flux, Glenn ^a   Bardies, Manuel ^b   Monsieurs, Myriam ^c   Savolainen, Sauli ^d   Strand, Sven Erik ^e   Lassmann, Michael ^f  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSERM   (France)

^c GHENT UNIVERSITY   (Belgium)

^d UNIVERSITY OF HELSINKI   (Finland)

^e LUND UNIVERSITY   (Sweden)

^f UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Dosimetry; PET; SPECT; Targeted radionuclide therapy

Indexed keywords

I 124; IODINE 131; RADIOISOTOPE; TECHNETIUM 99M; UNCLASSIFIED DRUG; YTTRIUM 86; YTTRIUM 90;

CANCER; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DOSE CALCULATION; DOSIMETRY; DRUG HALF LIFE; HUMAN; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; MONTE CARLO METHOD; PHYSICIAN; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIATION SCATTERING; REVIEW; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL IMAGING; TREATMENT PLANNING;

EID: 33646447666     PISSN: 09393889     EISSN: None     Source Type: Journal    
DOI: 10.1078/0939-3889-00291     Document Type: Article

References (119)

1. Chatal, J.F., Hoefnagel, C.A.: Radionuclide therapy. Lancet 354 (1999) 931-935
2. Nuis, A.: Health protection of individuals against the dangers of ionising radiation in relation to medical exposure: Council directive 97/43 EURATOM 30-6-1997
3. Dept of Health. The Ionising Radiation (Medical Exposure) Regulations 2000. SI 2000 No. 1059. 2000
4. DeNardo, S.J.: Tumor-targeted radionuclide therapy: Trial design driven by patient dosimetry. J Nucl Med 41 (2000) 104-106
5. Hoefnagel, C.A., Clarke, S.E., Fischer, M., Chatal, J.F., Lewington, V.J., Nilsson, S., Troncone, L., Vieira, M.R.: Radionuclide therapy practice and facilities in Europe. EANM Radionuclide Therapy Committee. Eur J Nucl Med 26 (1999) 277-82
6. Howell, R.W., Wessels, B.W., et al.: The MIRD perspective 1999. Medical Internal Radiation Dose Committee. J Nucl Med 40 (1999) 3S-10S
7. Loevinger, R.B.: MIRD primer for absorbed dose calculations. Society of Nuclear Medicine, New York 1988
8. Snyder, W.S., Ford, M.R., Warner, G.G., Watson, S.B.: Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs (PART I). Society of Nuclear Medicine. Reston, VA 1975
9. Marinelli, L., Quimby, E., Hine, G.: Dosage Determination with Radioactive Isotopes. II Practical Considerations in Therapy and Protection. American Journal of Roent and Radium Therapy 59 (1948) 260-280
10. ICRP53. International Commission on Radiological Protection. Radiation dose from Radiopharmaceuticals. ICRP Publication 53. Pergamon Press, New York 1988
11. Langmuir, V.K., Fowler, J.F., Knox, S.J., Wessels, B.W., Sutherland, R.M., Wong, J.Y.C.: Radiobiology of Radiolabeled Antibody Therapy As Applied to Tumor Dosimetry. Medical Physics 20 (1993) 601-610
12. ICRU Report 67 - Dose Specifications in Nuclear Medicine. ICRU 2002
13. Wiseman, G.A., Leigh, B., Erwin, W.D., Lamonica, D., Kornmehl, E., Spies, S.M., Silverman, D.H.S., Witzig, T.E., Sparks, R.B., White, C.A.: Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 94 (2002) 1349-1357
14. Wiseman, G.A., White, C.A., Stabin, M., Dunn, W.L., Erwin, W., Dahlbom, M., Raubitschek, A., Karvelis, K., Schultheiss, T., Witzig, T.E., Belanger, R., Spies, S., Silverman, D.H.S., Berlfein, J.R., Ding, E., Grillo-Lopezs, A.J.: Phase I/II Y-90-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. European J Nucl Med 27 (2000) 766-777
15. Vose, J.M., Wahl, R.L., Saleh, M., Rohatiner, A.Z., Knox, S.J., Radford, J.A., Zelenetz, A.D., Tidmarsh, G.F., Stagg, R.J., Kaminski, M.S.: Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. Journal of Clinical Oncology 18 (2000) 1316-1323
16. Kostakoglu, L., Goldsmith, S.J., Buchegger, F., Lewington, V., Leonard, J.P., Illidge, T., Ketterer, N., Kovacsovics, T., Valente, N., Bischof-Delaloye, A.: Preliminary results of a multicenter dosimetry, efficacy and safety study with iodine-131 tositumomab in treatment of non-Hodgkin's lymphoma (NHL). European J Nucl Med 28 (2001) OS73
17. Wiseman, G.A., White, C.A., Sparks, R.B., Erwin, W.D., Podoloff, D.A., Lamonica, D., Bartlett, N.L., Parker, J.A., Dunn, W.L., Spies, S.M., Belanger, R., Witzig, T.E., Leigh, B.R.: Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin (TM) radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Critical Reviews in Oncology Hematology 39 (2001) 181-194
18. Rajendran, J.G., Eary, J.F., Bensinger, W., Durack, L.D., Vernon, C., Fritzberg, A.: High-dose Ho-166-DOTMP in myeloablative treatment of multiple myeloma: Pharmacokinetics, biodistribution, and absorbed dose estimation. J Nucl Med 43 (2002) 1383-1390
19. Virgolini, I., Britton, K., Buscombe, J., Moncayo, R., Paganelli, G., Riva, P.: In-111- and Y-90-DOTA-lanreotide: Results and implications of the MAURITIUS trial. Seminars in Nuclear Medicine 32 (2002) 148-155
20. Flower, M.A., Fielding, S.L.: Radiation dosimetry for I-131-mIBG therapy of neuroblastoma. Physics in Medicine and Biology 41 (1996) 1933-1940
21. Luster, M., Sherman, S.I., Skarulis, M.C., Reynolds, J.R., Lassmann, M., Hanscheid, H., Reiners, C.: Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. European J Nucl Med and Molecular Imaging 30 (2003) 1371-1377
22. Koral, K.F., Dewaraja, Y., Li, J., Lin, Q., Regan, D.D., Zasadny, K.R., Rommelfanger, S.G., Francis, I.R., Kaminski, M.S., Wahl, R.L.: Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients. J Nucl Med 44 (2003) 457-464
23. Kendler, D., Donnemiller, E., Oberladstatter, M., Erler, H., Gabriel, M., Riccabona, G.: An individual dosimetric approach to 153Sm-EDTMP therapy for pain palliation in bone metastases in correlation with clinical results. Nucl Med Commun 25 (2004) 367-373
24. Meredith, R., Shen, S., Macey, D., Khazaeli, M.B., Carey, D., Robert, F, LoBuglio, A.: Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy. Cancer Biother Radiopharm 18 (2003) 393-404
25. Siegel, J.A., Thomas, S.R., Stubbs, J.B., Stabin, M.G., Hays, M.T., Koral, K.F., Robertson, J.S., Howell, R.W., Wessels, B.W., Fisher, D.R., Weber, D.A., Brill, A.B.: MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 40 (1999) 37S-61S
26. Dewaraja, Y.K., Ljungberg, M., Koral, K.F.: Accuracy of I-131 tumor quantification in radioimmunotherapy using SPECT imaging with an ultra-high-energy collimator: Monte Carlo study. J Nucl Med 41 (2000) 1760-1767
27. DeNardo, S.J., Kramer, E.L., ODonnell, R.T., Richman, C.M., Salako, Q.A., Shen, S., Noz, M., Glenn, S.D., Ceriani, R.L., DeNardo, G.L.: Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: Results of a phase I clinical trial. J Nucl Med 38 (1997) 1180-1185
28. Sjogreen, K., Ljungberg, M., Strand, S.E.: An activity quantification method based on registration of CT and whole-body scintillation camera images, with application to I-131. J Nucl Med 43 (2002) 972-982
29. Koral, K.F., Zasadny, K.R., Swailem, F.M., Buchbinder, S.F., Francis, I.R., Kaminski, M.S., Wahl, R.L.: Importance of Intra-Therapy Single-Photon Emission Tomographic Imaging in Calculating Tumor Dosimetry for A Lymphoma Patient. European J Nucl Med 18 (1991) 432-435
30. Erdi, A.K., Wessels, B.W., Dejager, R., Erdi, Y.E., Atkins, F.B., Yorke, E.D., Smith, L., Huang, E., Smiddy, M., Murray, J., Varma, V.M., McCabe, R., McNellis, R., John, C., Ney, A., Nochomovitz, L., Hanna, M.G.: Tumor-activity confirmation and isodose curve display for patients receiving iodine-131-labeled 16.88-human monoclonal-antibody. Cancer 73 (1994) 932-944
31. Koral, K.F., Zasadny, K.R., Kessler, M.L., Luo, J.Q., Buchbinder, S.F., Kaminski, M.S., Francis, I., Wahl, R.L.: CT-SPECT fusion plus conjugate views for determining dosimetry in iodine-131-monoclonal antibody therapy of lymphoma patients. J Nucl Med 35 (1994) 1714-1720
32. Korppi-Tommola, E.T., Kairemo, K.J.A., Jekunen, A.P., Niskanen, E.O., Savolainen, S.E.: Double-tracer dosimetry of organs in assessment of bone marrow involvement by two monoclonal antibodies. Acta Oncologica 35 (1996) 357-365
33. DeNardo, S.J., DeNardo, G.L., Kukis, D.L., Shen, S., Kroger, L.A., DeNardo, D.A., Goldstein, D.S., Mirick, G.R., Salako, Q., Mausner, L.F., Srivastava, S.C., Meares, C.E.: Cu-67-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med 40 (1999) 302-310
34. Koral, K.F., Li, J., Dewaraja, Y., Barrett, C.L., Regan, D.D., Zasadny, K.R., Rommelfanger, S.G., Francis, I.R., Kaminski, M.S., Wahl, R.L.: I-131 anti-B1 therapy/tracer uptake ratio using a new procedure for fusion of tracer images to computed tomography images. Clinical Cancer Research 5 (1999) 3004S-3009S
35. Lundqvist, H., Lubberink, M., Tolmachev, V., Lovqvist, A., Sundin, A., Beshara, S., Bruskin, A., Carlsson, J., Westlin, J.E.: Positron emission tomography and radioimmunotargeting - General aspects. Acta Oncologica 38 (1999) 335-341
36. Koral, K.F., Dewaraja, Y., Li, J., Barrett, C.L., Regan, D.D., Zasadny, K.R., Rommelfanger, S.G., Francis, I.R., Kaminski, M.S., Wahl, R.L.: Initial results for hybrid SPECT-conjugate-view tumor dosimetry in I-131-anti-B-1 antibody therapy of previously untreated patients with lymphoma. J Nucl Med 41 (2000) 1579-1586
37. Koral, K.F., Dewaraja, Y., Clarke, L.A., Li, J., Zasadny, K.R., Rommelfanger, S.G., Francis, I.R., Kaminski, M.S., Wahl, R.L.: Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: Preliminary report. Cancer Biotherapy and Radiopharmaceuticals 15 (2000) 347-355
38. Koral, K.F., Francis, I.R., Kroll, S., Zasadny, K.R., Kaminski, M.S., Wahl, R.L.: Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy - Conjugate views compared with a hybrid method. Cancer 94 (2002) 1258-1263
39. Orlova, A., Hoglund, J., Lubberink, M., Lebeda, O., Gedda, L., Lundqvist, H., Tolmachev, V., Sundin, A.: Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetry. Cancer Biotherapy and Radiopharmaceuticals 17 (2002) 385-396
40. Siegel, J.A., Wu, R.K., Maurer, A.H.: The Buildup Factor - Effect of Scatter on Absolute Volume Determination. J Nucl Med 26 (1985) 390-394
41. Guy, M.J., Castellano-Smith, I.A., Flower, M.A., Flux, G.D., Ott, R.J., Visvikis, D.: DETECT - Dual energy transmission estimation CT - for improved attenuation correction in SPECT and PET. IEEE Transactions on Nuclear Science 45 (1998) 1261-1267
42. Kolbert, K.S., Sgouros, G., Scott, A.M., Bronstein, J.E., Malane, R.A., Zhang, J.J., Kalaigian, H., McNamara, S., Schwartz, L., Larson, S.M.: Implementation and evaluation of patient-specific three-dimensional internal dosimetry. J Nucl Med 38 (1997) 301-308
43. Laitinen, J.O., Kairemo, K.J.A., Jekunen, A.P., Korppi-Tommola, T., Tenhunen, M.: The effect of three dimensional activity distribution on the dose planning of radioimmunotherapy for patients with advanced intraperitoneal pseudomyxoma. Cancer 80 (1997) 2545-2552
44. Sgouros, G., Squeri, S., Ballangrud, A.M., Kolbert, K.S., Teitcher, J.B., Panageas, K.S., Finn, R.D., Divgi, C.R., Larson, S.M., Zelenetz, A.D.: Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with I-131-anti-B1 antibody: Assessment of tumor dose-response. J Nucl Med 44 (2003) 260-268
45. Papavasileiou, P., Flux, G.D., Flower, M.A., Guy, M.J.: Automated CT marker segmentation for image registration in radionuclide therapy. Physics in Medicine and Biology 46 (2001) N269-N279
46. Strand, S.E., Jonsson, B.A., Ljungberg, M., Tennvall, J.: Radioimmunotherapy Dosimetry - A Review. Acta Oncologica 32 (1993) 807-817
47. Holmes, T., Mackie, T.R.: A Filtered Backprojection Dose Calculation Method for Inverse Treatment Planning. Medical Physics 21 (1994) 303-313
48. Larson, S.M., Divgi, C.R., Scott, A., Sgouros, G., Graham, M.C., Kostakoglu, L., Scheinberg, D., Cheung, N.K.V., Schlom, J., Finn, R.D.: Current status of radioimmunotherapy. Nuclear Medicine and Biology 21 (1994) 785-792
49. Strand, S.E., Ljungberg, M., Tennvall, J., Norrgren, K., Garkavij, M.: Radio-Immunotherapy Dosimetry with Special Emphasis on Spect Quantification and Extracorporeal Immuno-Adsorption. Medical & Biological Engineering & Computing 32 (1994) 551-561
50. Turner, J.H., Claringbold, P.G., Klemp, P.F.B., Cameron, P.J., Martindale, A.A., Glancy, R.J., Norman, P.E., Hetherington, E.L., Najdovski, L., Lambrecht, R.M.: Ho-166-Microsphere Liver Radiotherapy - A Preclinical Spect Dosimetry Study in the Pig. Nuclear Medicine Communications 15 (1994) 545-553
51. Giap, H.B., Macey, D.J., Bayouth, J.E., Boyer, A.L.: Validation of a dose-point kernel convolution technique for internal dosimetry. Physics in Medicine and Biology 40 (1995) 365-381
52. Giap, H.B., Macey, D.J., Podoloff, D.A.: Development of A SPECT-Based 3-Dimensional Treatment Planning System for Radioimmunotherapy. J Nucl Med 36 (1995) 1885-1894
53. Siegel, J.A., Zeiger, L.S., Order, S.E., Wallner, P.E.: Quantitative bremsstrahlung single-photon emission computed tomographic imaging - use for volume, activity, and absorbed dose calculations. International Journal of Radiation Oncology Biology Physics 31 (1995) 953-958
54. Furhang, E.E., Chui, C.S., Sgouros, G.: A Monte Carlo approach to patient-specific dosimetry. Medical Physics 23 (1996) 1523-1529
55. Tristam, M., Alaamer, A.S., Fleming, J.S., Lewington, V.J., Zivanovic, M.A.: Iodine-131-metaiodobenzylguanidine dosimetry in cancer therapy: Risk versus benefit. J Nucl Med 37 (1996) 1058-1063
56. Behr, T.M., Sharkey, R.M., Juweid, M.E., Dunn, R.M., Ying, Z.L., Zhang, C.H., Siegel, J.A., Goldenberg, D.M.: Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies. J Nucl Med 38 (1997) 409-418
57. Behr, T.M., Sharkey, R.M., Juweid, M.E., Dunn, R.M., Vagg, R.C., Ying, Z.L., Zhang, C.H., Swayne, L.C., Vardi, Y., Siegel, J.A., Goldenberg, D.M.: Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 38 (1997) 858-870
58. Flux, G.D., Webb, S., Ott, R.J., Chittenden, S.J., Thomas, R.: Three-dimensional dosimetry for intralesional radionuclide therapy using mathematical modeling and multimodality imaging. J Nucl Med 38 (1997) 1059-1066
59. Furhang, E.E., Chui, C.S., Kolbert, K.S., Larson, S.M., Sgouros, G.: Implementation of a Monte Carlo dosimetry method for patient-specific internal emitter therapy. Medical Physics 24 (1997) 1163-1172
60. Koral, K.F., Lin, S.H., Fessier, J.A., Kaminski, M.S., Wahl, R.L.: Preliminary results from intensity-based CT-SPECT fusion in I-131 anti-B1 monoclonal-antibody therapy of lymphoma. Cancer 80 (1997) 2538-2544
61. Leichner, P.K., Akabani, G., Colcher, D., Harrison, K.A., Hawkins, W.G., Eckblade, M., Baranowska-Kortylewicz, J., Augustine, S.C., Wisecarver, J., Tempero, M.A.: Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. J Nucl Med 38 (1997) 512-516
62. Tempero, M., Leichner, P., Baranowska-Kortylewicz, J., Harrison, K., Augustine, S., Schlom, J., Anderson, J., Wisecarver, J., Colcher, D.: High-dose therapy with (90)yttrium-labeled monoclonal antibody CC49: A phase I trial. Clinical Cancer Research 6 (2000) 3095-3102
63. Colnot, D.R., Quak, J.J., Roos, J.C., van Lingen, A., Wilhelm, A.J., van Kamp, G.J., Huijgens, P.C., Snow, G.B., van Dongen, G.A.M.S.: Phase I therapy study of Re-186-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 41 (2000) 1999-2010
64. Van Laere, K., Koole, M., Kauppinen, T., Monsieurs, M., Bouwens, L., Dierck, R.: Nonuniform transmission in brain SPECT using Tl-201, Gd-153, and Tc-99m static line sources: Anthropomorphic dosimetry studies and influence on brain quantification. J Nucl Med 41 (2000) 2051-2062
65. Gonzalez, D.E., Jaszczak, R.J., Bowsher, J.E., Akabani, G., Greer, K.L.: High-resolution absolute SPECT quantitation for I-131 distributions used in the treatment of lymphoma: A phantom study. Transactions on Nuclear Science 48 (2001) 707-714
66. Thierens, H.M., Monsieurs, M.A., Brans, B., Van Driessche, T., Christiaens, I., Dierckx, R.A.: Dosimetry from organ to cellular dimensions. Computerized Medical Imaging and Graphics 25 (2001) 187-193
67. Ljungberg, M., Sjogreen, K., Liu, X.W., Frey, E., Dewaraja, Y., Strand, S.E.: A 3-dimensional absorbed dose calculation method based on quantitative SPECT for radionuclide therapy: Evaluation for I-131 using Monte Carlo simulation. J Nucl Med 43 (2002) 1101-1109
68. 131I Radionuclide Therapy Using Patient-Specific,3-Dimensional Methods for SPECT Reconstruction and Absorbed Dose Calculation. J Nucl Med 46 (2005) 840-849
69. Boucek, J.A., Turner, J.H.: Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in (131)I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 32 (2005) 458-469
70. De Jong, M., Valkema, R., Van Gameren, A., Van Boven, H., Bex, A., Van De Weyer, E.P., Burggraaf, J.D., Korner, M., Reubi, J.C., Krenning, E.P.: Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. J Nucl Med 45 (2004) 1168-1171
71. King, M., Farncombe, T.: An overview of attenuation and scatter correction of planar and SPECT data for dosimetry studies. Cancer Biother Radiopharm 18 (2003) 181-190
72. Ljungberg, M., Frey, E., Sjogreen, K., Liu, X., Dewaraja, Y., Strand, S.E.: 3D absorbed dose calculations based on SPECT: evaluation for 111-In/90-Y therapy using Monte Carlo simulations. Cancer Biother Radiopharm 18 (2003) 99-107.
73. Guy, M.J., Flux, G.D., Papavasileiou, P., Flower, M.A., Ott, R.J.: RMDP: a dedicated package for 131I SPECT quantification, registration and patient-specific dosimetry. Cancer Biother Radiopharm 18 (2003) 61-69
74. Sjorgreen, K., Ljungberg, M., Strand, S.E.: Parameters influencing volume and activity quantitation in SPECT. Acta Oncol 35 (1996) 323-330
75. Beekman, F.J., Kamphuis, C., Frey, E.G.: Scatter compensation methods in 3D iterative SPECT reconstruction: A simulation study. Physics in Medicine and Biology 42 (1997) 1619-1632
76. [ 76] Bruyant, P.P.: Analytic and iterative reconstruction algorithms in SPECT. J Nucl Med 43 (2002) 1343-1358
77. Wernick, M., Aarsvold, J.: Emission Tomography: The Fundamentals of PET and SPECT. Academic Press, 2004
78. [ 78] Bailey, D.L.: Transmission scanning in emission tomography. Eur J Nucl Med 25 (1998) 774-787
79. Ljungberg, M., Strand, S.E.: Attenuation and scatter correction in SPECT for sources in a nonhomogeneous object: a monte Carlo study. J Nucl Med 32 (1991) 1278-1284
80. Damen, E.M., Muller, S.H., Boersma, L.J., de Boer, R.W., Lebesque, J.V.: Quantifying local lung perfusion and ventilation using correlated SPECT and CT data. J Nucl Med 35 (1994) 784-792
81. [ 81] King, M.A., Tsui, B.M., Pan, T.S., Glick, S.J., Soares, E.J.: Attenuation compensation for cardiac single-photon emission computed tomographic imaging: Part 2. Attenuation compensation algorithms. J Nucl Cardiol 3 (1996) 55-64
82. Licho, R., Glick, S.J., Xia, W., Pan, T.S., Penney, B.C., King, M.A.: Attenuation compensation in 99mTc SPECT brain imaging: a comparison of the use of attenuation maps derived from transmission versus emission data in normal scans. J Nucl Med 40 (1999) 456-463
83. Zaidi, H., Hasegawa, B.: Determination of the attenuation map in emission tomography. J Nucl Med 44 (2003) 291-315
84. Zaidi, H.: Relevance of accurate Monte Carlo Modeling in nuclear medical imaging. Medical Physics 26 (1999) 574-608
85. [ 85] Buvat, I., Castiglioni, I.: Monte Carlo simulations in SPECT and PET. The quarterly Journal of Nuclear Medicine 46 (2002) 48-61
86. Ljungberg, M., Strand, S.E., King, M.A.: Monte Carlo Calculation in Nuclear Medicine: Applications in Diagnostic Imaging. IOP Publishing. Bristol and Philadelphia 1998
87. Haidi, H., Sgouros, G.: Therapeutic Applications of Monte-Carlo Calculations in Nuclear Medicine. IOP Publishing. Bristol and Philadelphia 2003
88. Berger, M.J.: MonteCarlo calculation of the penetration and diffusion of fast charged particles. In: Alder, B., Fernbach, S., Rotenberg, M. (eds.): Methods in computational physics Vol. 1. Academic Press, New York 1963
89. Nelson, W.R., Hirayama, H., Rogers, D.W.O.: The EGS4 code system. Stanford Linear Accelerator Center report SLAC-265, 1985
90. Briesmeister, J.F. (Ed.): MCNP - A General Monte Carlo N-Particle Transport Code. Los Alamos National Laboratory report LA-12625-M, November 1993
91. Agostinelli, S., Allisonas, J., Amakoe, K. et al.: Geant4 - a simulation toolkit. Nuclear Instruments and Methods in Physics Research. NIM A 506 (2003) 250-303
92. Jan, S., Santin, G., Strul, D., Staelens, S., Assie, K., Autret, D., Avner, S., Barbier, R., Bardies, M., Bloomfield, P.M., Brasse, D., Breton, V., Bruyndonckx, P., Buvat, I., Chatziioannou, A.F., Choi, Y., Chung, Y.H., Comtat, C., Donnarieix, D., Ferrer, L., Glick, S.J., Groiselle, C.J., Guez, D., Honore, P.F., Kerhoas-Cavata, S., Kirov, A.S., Kohli, V., Koole, M., Krieguer, M., van der Laan, D.J., Lamare, F., Largeron, G., Lartizien, C., Lazaro, D., Maas, M.C., Maigne, L., Mayet, F., Melot, F., Merheb, C., Pennacchio, E., Perez, J., Pietrzyk, U., Rannou, F.R., Rey, M., Schaart, D.R., Schmidtlein, C.R., Simon, L., Song, T.Y., Vieira, J.M., Visvikis, D., Van de Walle, R., Wieers, E., Morel, C.: GATE: a simulation toolkit for PET and SPECT. Phys Med Biol 49 (2004) 4543-4561
93. Dewaraja, Y.K., Ljungberg, M., Bose, A., Majumdar, A., Koral, K.A.: parallel Monte Carlo code for planar and SPECT imaging: implementation, verification and applications in I-131 SPECT. Comp Meth Progr Biomed 67 (2002) 115-124
94. Zaidi, H., Montandon, M.L., Slosman, D.O.: Magnetic resonance imaging-guided attenuation and scatter corrections in three-dimensional brain positron emission tomography. Med Phys 30 (2003) 937-948
95. 124I used in positron tomography of the thyroid. Phys Med Biol 31 (1986) 789-791
96. Ott, R.J., Batty, V., Webb, B.S., Flower, M.A., Leach, M.O., Clack, R., Marsden, P.K., McCready, V.R., Bateman, J.E., Sharma, H., et al.: Measurement of radiation dose to the thyroid using positron emission tomography. Br J Radiol 60 (1987) 245-251
97. Flower, M.A., Irvine, A.T., Ott, R.J., Kabir, F., McCready, V.R., Harmer, C.L., Sharma, H.L., Smith, A.G.: Thyroid imaging using positron emission tomography - a comparison with ultrasound imaging and conventional scintigraphy in thyrotoxicosis. Br J Radiol 63 (1990) 325-330
98. Westera, G., Reist, H.W., Buchegger, F., Heusser, C.H., Hardman, N., Pfeiffer, A., Sharma, H.L., von Schulthess, G.K., Mach, J.P.: Radioimmuno positron emission tomography with monoclonal antibodies: a new approach to quantifying in vivo tumour concentration and biodistribution for radioimmunotherapy. Nucl Med Commun 12 (1991) 429-437
99. Pentlow, K.S., Graham, M.C., Lambrecht, R.M., Cheung, N.K., Larson, S.M.: Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys 18 (1991) 357-366
100. Larson, S.M., Pentlow, K.S., Volkow, N.D., Wolf, A.P., Finn, R.D., Lambrecht, R.M., Graham, M.C., Di Resta, G., Bendriem, B., Daghighian, F., et al.: PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med 33 (1992) 2020-2023
101. 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography. Br J Radiol 65 (1992) 787-791
102. Pentlow, K.S., Graham, M.C., Lambrecht, R.M., Daghighian, F., Bacharach, S.L., Bendriem, B., Finn, R.D., Jordan, K., Kalaigian, H., Karp, J.S., Robeson, W.R., Larson, S.M.: Quantitative imaging of iodine-124 with PET. J Nucl Med 37 (1996) 1557-1562
103. Lubberink, M., Lundqvist, H., Westlin, J.E., Toltnachev, V., Schneider, H., Lovqvist, A., Sundin, A., Carlsson, J.: Positron emission tomography and radioimmunotargeting - aspects of quantification and dosimetry. Acta Oncol 38 (1999) 343-349
104. Crawford, D.C., Flower, M.A., Pratt, B.E., Hill, C., Zweit, J., McCready, V.R., Harmer, C.L.: Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography. Eur J Nucl Med 24 (1997) 1470-1478
105. Eschmann, S.M., Reischl, G., Bilger, K., Kupferschlager, J., Thelen, M.H., Dohmen, B.M., Besenfelder, H., Bares, R.: Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging 29 (2002) 760-767
106. Sgouros, G., Kolbert, K.S., Sheikh, A., Pentlow, K.S., Mun, E.F., Barth, A., Robbins, R.J., Larson, S.M.: Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 45 (2004) 1366-1372
107. Rosch, F., Herzog, H., Stolz, B., Brockmann, J., Kohle, M., Muhlensiepen, H., Marbach, P., Muller-Gartner, H.W.: Uptake kinetics of the somatostatin receptor ligand [Y-86]DOTA-DPhe(1)-Tyr(3)-octreotide ([Y-86]SMT487) using positron emission tomography in non-human primates and calculation of radiation closes of the Y-90-labelled analogue. Eur J Nucl Med 26 (1999) 358-366
108. Forster, G.J., Engelbach, M.J., Brockmann, J.J., Reber, H.J., Buchholz, H.G., Macke, H.R., Rosch, F.R., Herzog, H.R., Bartenstein, P.R.: Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA- octreotide. Eur J Nucl Med 28 (2001) 1743-1750
109. Jamar, F., Barone, R., Mathieu, I., Walrand, S., Labar, D., Carlier, P., de Camps, J., Schran, H., Chen, T., Smith, M.C., Bouterfa, H., Valkema, R., Krenning, E.P., Kvols, L.K., Pauwels, S.: 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487) - a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 30 (2003) 510-518
110. Palm, S., Enmon, R.M. Jr, Matei, C., Kolbert, K.S., Xu, S., Zanzonico, P.B., Finn, R.L., Koutcher, J.A., Larson, S.M., Sgouros, G.: Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med 44 (2003) 1148-1155
111. Buchholz, H.G., Herzog, H., Forster, G.J., Reber, H., Nickel, O., Rosch, F., Bartenstein, P.: PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction. Eur J Nucl Med Mol Imaging 30 (2003) 716-720
112. 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31 (2004) 1386-1392
113. Barone, R., Borson-Chazot, F., Valkema, R., Walrand, S., Chauvin, F., Gogou, L., Kvols, L.K., Krenning, E.P., Jamar, F., Pauwels, S.: Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 46 (2005) 99S-106S
114. Pauwels, S., Barone, R., Walrand, S., Borson-Chazot, F., Valkema, R., Kvols, L.K., Krenning, E.P., Jamar, F.: Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med 46 (2005) 92S-98S
115. Ugur, O., Kothari, P.J., Finn, R.D., Zanzonico, P., Ruan, S., Guenther, I., Maecke, H.R., Larson, S.M.: Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol. 29 (2002) 147-57
116. Lubberink, M., Lundqvist, H., Tolmachev, V.: Production, PET performance and dosimetric considerations of Ce-134/La-134, an Auger electron and positron-emitting generator for radionuclide therapy. Physics in Medicine and Biology 47 (2002) 615-629
117. Sgouros, G., Barest, G., Thekkumthala, J., Chui, C., Mohan, R., Bigler, R.E., Zanzonico, P.B.: Treatment planning for internal radionuclide therapy - 3-dimensional dosimetry for non-uniformly distributed radionuclides. J Nucl Med 31 (1990) 1884-1891
118. Bolch, W.E., Bouchet, L.G., Robertson, J.S., Wessels, B.W., Siegel, J.A., Howell, R.W., Erdi, A.K., Aydogan, B., Costes, S., Watson, E.E.: MIRD pamphlet No. 17: The dosimetry of nonuniform activity distributions - Radionuclide S values at the voxel level. J Nucl Med 40 (1999) 11S-36S
119. Hasegawa, B., Tang, H.R., Da Silva, A.J., Wong, K.H., Iwata, K., Wu, M.C.: Dual-modality imaging. Nuclear Instruments & Methods in Physics Research Section A - Accelerators Spectrometers Detectors and Associated Equipment 471 (2001) 140-144